Schwannoma (neurilemmoma) is a benign encapsulated tumor originating from Schwann cells of the peripheral nerve sheath and is the most common peripheral nerve sheath tumor. The fundamental difference from neurofibroma is its eccentric position to the nerve — it pushes the nerve aside without infiltration and can be surgically separated from the nerve. Common between ages 20-50 with no gender predilection. Superficial schwannomas are located in subcutaneous tissue, commonly on flexor surfaces, most frequently affecting upper extremity nerves. Clinically presents as a slow-growing, mobile (perpendicular to nerve axis but limited along axis — 'positive Tinel sign'), sometimes tender nodule. Ultrasonography is the primary modality — well-defined hypoechoic solid nodule, prominent posterior acoustic enhancement (myxoid Antoni B component), eccentric position to nerve, and 'tail sign' (entering/exiting nerve ends) are characteristic findings.
Age Range
20-65
Peak Age
45
Gender
Equal
Prevalence
Uncommon
Schwannoma arises from monoclonal proliferation of Schwann cells. Inactivating mutations in the NF2 gene (22q12.2) are found in most schwannomas — NF2 protein (merlin/schwannomin) is a tumor suppressor regulating cell-cell contact inhibition. Merlin loss → Hippo/YAP pathway dysregulation → uncontrolled Schwann cell proliferation. Histologically contains two distinct areas: (1) Antoni A — compact, organized spindle cells forming palisading (fence) pattern (Verocay bodies), high cellularity, low water content; (2) Antoni B — loose myxoid stroma, low cellularity, high water content, microcystic degeneration areas. These two components determine US and MRI findings: Antoni A high cellularity → hypoechoic solid area on US (low impedance); Antoni B high water content → prominent posterior enhancement on US (low attenuation) and T2 hyperintensity on MRI (long T2). The tumor is surrounded by a fibrous capsule and sits eccentrically to the nerve — the nerve passes displaced along one edge of the capsule. This eccentric position is demonstrable on US and is the most important criterion for differentiating from neurofibroma: neurofibroma grows from the nerve center (intraneural). The capsule facilitates surgical resection — schwannoma can be removed preserving nerve function (intracapsular enucleation).
Three cardinal US findings of schwannoma: (1) eccentric position to nerve — nerve displaced along capsule edge; (2) tail sign — entering/exiting nerve at ends; (3) prominent posterior enhancement — myxoid Antoni B component. This triad makes schwannoma diagnosis with high confidence and differentiates from neurofibroma (neurofibroma: intraneural, target sign, less prominent enhancement).
On B-mode US, schwannoma appears as a well-defined, oval or fusiform, hypoechoic solid nodule with prominent posterior acoustic enhancement. Internal structure is generally homogeneously hypoechoic, but in large lesions, heterogeneous distribution of Antoni A and B areas may create variable echogenicity. Cystic degeneration areas (Antoni B myxoid degeneration) may appear as anechoic foci. Posterior enhancement is a distinguishing feature — the high water content of myxoid Antoni B component attenuates sound at a low rate. The capsule may be seen as a thin hyperechoic line. Size is usually 2-5 cm.
Report Sentence
A well-defined hypoechoic solid nodule with prominent posterior acoustic enhancement is seen; consistent with schwannoma.
Schwannoma is eccentric to the nerve — the nerve passes displaced along one edge of the tumor capsule. On transverse US section, the nerve is NOT surrounded by the mass (unlike neurofibroma); it appears as a thin echogenic structure at one edge of the capsule. On longitudinal section, the nerve runs along one side of the lesion. This eccentric position is the most reliable US criterion for schwannoma-neurofibroma differentiation. A capsule barrier exists between nerve and tumor → nerve can be preserved during surgical removal (intracapsular enucleation).
Report Sentence
The lesion is eccentric to the nerve with the nerve displaced along the capsule edge; consistent with schwannoma.
On longitudinal section, the entering and exiting nerve appears as a thin echogenic line at the proximal and distal ends of the schwannoma — 'tail sign'. Tail sign is characteristic of nerve-origin tumors (both schwannoma and neurofibroma) and confirms nerve origin. In schwannoma, the nerve enters and exits from one edge (eccentric); in neurofibroma, the nerve passes through the center.
Report Sentence
Tail sign is seen at proximal and distal ends, consistent with a nerve-origin tumor.
Schwannoma shows variable vascularity on color and power Doppler. Small lesions have minimal or no vascularity. Internal vascular signals may be seen in large lesions — neovascularization in Antoni A areas. Peripheral rim vascularity reflects capsular feeding vessels. 'Ancient' schwannomas have decreased vascularity due to degenerative changes. Increased vascularity alone is not a malignancy criterion but combined with rapid growth should raise MPNST suspicion.
Report Sentence
Minimal internal vascularity is detected within the lesion on Doppler.
On MRI T2, schwannoma shows marked heterogeneous hyperintensity. Antoni B areas (myxoid stroma, high water) are markedly T2 hyperintense; Antoni A areas (compact cellular) show intermediate T2 signal. This heterogeneity is also described as 'fascicular sign'. Surrounding subcutaneous fat may form a ring — 'split-fat sign': tumor splits subcutaneous fat and fat surrounds the capsule. Low-intermediate T1 signal, heterogeneous post-contrast enhancement (more prominent in Antoni A areas). In large or 'ancient' schwannomas, cystic degeneration, hemorrhage, and calcification may add signal heterogeneity.
Report Sentence
A heterogeneously T2-hyperintense, fusiform nerve-associated lesion with split-fat sign is seen; consistent with schwannoma.
In long-standing ('ancient') schwannomas, myxoid degeneration in Antoni B areas progresses forming cystic areas — seen as anechoic or hypoechoic foci on US. Cystic degeneration contributes to prominent posterior enhancement. Hemorrhage (hyperechoic foci) and calcification (hyperechoic + shadowing) may also be seen. These degenerative changes cause heterogeneous appearance and may raise malignancy suspicion — but ancient schwannoma is completely benign. Size usually >3 cm.
Report Sentence
Cystic degeneration areas within the lesion suggest 'ancient' schwannoma.
Criteria
Most common form. Solitary, encapsulated, Antoni A + B areas.
Distinct Features
Homogeneously hypoechoic on US, posterior enhancement, eccentric. Surgery: intracapsular enucleation, nerve preserved.
Criteria
Long-standing lesion. Degenerative changes: cystic degeneration, hemorrhage, calcification, nuclear atypia.
Distinct Features
Heterogeneous on US (cystic + solid + calcified). May raise malignancy suspicion but is completely benign. Nuclear atypia from degeneration.
Criteria
Multiple nodules, along plexus, may be NF2-associated.
Distinct Features
Must differentiate from plexiform neurofibroma — schwannoma eccentric, neurofibroma intraneural. NF2 should be evaluated.
Criteria
Antoni A-dominant, high cellularity, mitoses may be present. May be confused with MPNST.
Distinct Features
Less posterior enhancement on US (minimal Antoni B). Less T2 hyperintense on MRI. Biopsy may be needed to exclude MPNST.
Distinguishing Feature
Neurofibroma grows from nerve center (intraneural), shows target sign (peripheral hyperechoic + central hypoechoic), cannot be surgically separated. Schwannoma is eccentric, no target sign (homogeneously hypoechoic), prominent posterior enhancement, surgically separable.
Distinguishing Feature
Ganglion cyst is completely cystic (anechoic), compressible, connected to joint/tendon sheath (stalk/pedicle), avascular. Schwannoma is solid (hypoechoic), non-compressible, nerve-associated (tail sign), posterior enhancement unusual in solid lesion → myxoid component.
Distinguishing Feature
Dermatofibroma within dermis, no nerve association, dimple sign positive, no posterior enhancement, small (<2 cm). Schwannoma subcutaneous, nerve-associated (tail sign), prominent posterior enhancement, larger (2-5 cm).
Urgency
routineManagement
surgicalBiopsy
Not NeededFollow-up
no-follow-upSchwannoma is completely benign with very low malignant transformation risk (<1%). Preoperative diagnosis is confidently made with typical US (eccentric, tail sign, posterior enhancement) and MRI (heterogeneous T2, split-fat sign) findings without biopsy. Asymptomatic small lesions may be observed. For symptomatic lesions (pain, neurological deficit, cosmetic), intracapsular enucleation is performed — nerve function is preserved because the tumor capsule forms a nerve-tumor barrier (fundamental surgical advantage over neurofibroma). Recurrence rate is very low (<5%). In NF2 patients, bilateral vestibular schwannomas and multiple peripheral schwannomas require genetic counseling and annual MRI surveillance.
Schwannomas are benign lesions and surgical excision is curative. Unlike neurofibroma, it can be separated from the nerve — nerve can be preserved during surgery. Malignant transformation (malignant schwannoma) is extremely rare. Multiple schwannomas may occur in NF2 patients — bilateral vestibular schwannomas are diagnostic criteria for NF2. Schwannomatosis (non-NF2 multiple schwannomas) is a separate genetic syndrome (SMARCB1/LZTR1 mutations). Cystic degeneration and hemorrhage may occur in large lesions, causing heterogeneity and potentially complicating the differential diagnosis.